Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
PEG-irinotecan by JenKem Technology for Gastric Cancer: Likelihood of Approval
PEG-irinotecan is under clinical development by JenKem Technology and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...